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care admittance, Charlson co-morbidity score, state of residence, and gender all
were significant predictors of AD medication use (p  0.0001 for all variables).
Racial/ethnic disparities were observed with respect to exposure to a ChEI or me-
mantine between Non-Hispanic Whites and Hispanics (in favor of Hispanics) in
California (p  0.002) and Florida (p  0.0001), between Non-Hispanic Whites and
Non-Hispanic Others (in favor of Non-Hispanics Others) across all states, between
Non-Hispanic Blacks andNon-Hispanic Others (in favor of Non-Hispanic Others) in
California (p  0.0001) and New York (p  0.0001), and between Hispanics and
Non-Hispanic Others (in favor of Non-Hispanic Others) in California (p  0.001),
Florida (p  0.013), and New York (p  0.0001). CONCLUSIONS: Disparities in AD
medication use among minority-to-minority populations are just as prevalent, if
not higher, than minority-white disparities. Furthermore, geographical location
was important predictor of health disparities.
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DISCREPANCIES IN HOSPITALIZATION TRENDS BY EPILEPSY AMONG THREE
LATIN AMERICA COUNTRIES
Soares C, Viana KP, Santana PK, Figueiredo D, Machado M
GlaxoSmithKline, Rio de Janeiro, Brazil
OBJECTIVES: Epilepsy has been the focus of several primary care programs across
LatinAmerica region due to its high prevalence and related burden. Hospitalization
could be used as an indicator for frequency ofmore severe cases with uncontrolled
and frequent seizures. Thus, hospital admission trends could be instrumental to
understanding treatment gaps and support decision making. Our objective was to
evaluate hospital admission trend by Epilepsy in three Latin America Countries.
METHODS: Hospitalization data were extracted from Public Healthcare Databases
from Brazil, Chile and Mexico covering 2001-2008. Country and age-specific hospi-
tal admission frequencies due to Epilepsy (ICD G40) in people 14 years-old were
calculated. Three age range categories were created: 15-29; 30-44; 45-59 and 60.
We built general estimating equation models with Poisson distributions to evalu-
ate hospital admissions time trends. Further, the differences between the age
ranges were also estimated. RESULTS:Means of annual hospitalization rates were
similar in Brazil and Chile (2.63 and 2.79, respectively) but comparatively low in
Mexico (0.39). The three countries showed different in-hospital patterns over time.
Brazil had a downward tendency with an annual ratio of 0.982 (p0.001) and Chile
a relatively flat one (pNS). On the other hand, Mexico presented an upward trend,
with an annual ratio of 1.043 (p0.001). Mean hospitalization rates were higher in
older age categories in Brazil and Chile and the younger ones in Mexico. The age
categories were following the trends showed by their respective countries in the
overall analysis. CONCLUSIONS: Despite having qualitatively similar assistance
programs across the region, the countries showed different rates and patterns of
hospitalization due to Epilepsy. Direct comparison between countries should be
examined cautiously due to important differences in their health care systems and
data collection process.
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OBJECTIVES: To compare short and long-term all cause health care resource utili-
zation among newly diagnosed multiple sclerosis (MS) patients enrolled in Man-
aged Medicaid or Commercial health plans. METHODS: We used the I3 InVision
Data Mart to identify continuously enrolled patients 18 years of age with at least
two ICD-9 codes for multiples sclerosis (340.xx) between the dates of June 1, 2006
and March 31, 2010. Baseline patient characteristics as well as thirty-day and 24
month all cause health care resource utilization and costs were assessed using
Analysis of Variance (ANOVA) for continuous variables and Chi-squared statistics
for continuous variables.RESULTS:Medicaid beneficiariesweremore likely to have
more psycho-social limitations (23.5%; p 0.0001) than their counterparts insured
through commercial plans. Within the first 30 days of diagnosis, Medicaid HMO
beneficiaries were more likely to be hospitalized (p  0.006) and utilize Emergency
Department services (p  0.0001). In addition, Medicaid HMO beneficiaries were
20% less likely to have a claim for a Neurologist vist and 50% less likely to be
prescribed disease modifying therapies than commercial enrollees. Long-term ac-
cess tomedical servicesmirrored that observed in the short termwith higher rates
of hospitalization (p  0.006) and emergency department use (p  0.001) and less
access to Neurologist (p  0.001) and disease modifying treatment (p  0.027).
CONCLUSIONS: Opportunities exist to support newly diagnosed MS patients en-
rolled inMedicaidHMOplans. The development and implementation of innovative
managed care strategies will ensure that Medicaid HMO beneficiaries received ac-
cess to specialty care and approved treatments at the same rate as their counter-
parts enrolled in commercial health plans.
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OBJECTIVES: The study examined determinants of prescription drug expenditures
in patients with Multiple Sclerosis (MS) in United States (US). METHODS: Retro-
spective cross-sectional study was conducted using the 2002-2009 Medical Expen-
diture Panel Survey (MEPS) data, a nationally representative data on the commu-
nity dwelling, non-institutionalized US population. The study sample included
patients diagnosed with MS (ICD-9-CM: 340). Weighted descriptive statistics were
performed to estimate the total and prescription drug expenditures. Multiple Or-
dinary Least Square regression analysis within the conceptual framework of An-
derson Behavioral Model was performed to identify factors associated with pre-
scription drug expenditures. The log transformation of the prescription drug
expenditures was carried out to address skewed nature of cost data. RESULTS: An
estimated of 4.1 million patients were diagnosed with MS during 2002-2009. The
total average expenditure for MS patients was $17,619 (95% CI: 16,385-18,913). Of
which 44%was attributable to the prescription drugs cost, i.e. $7760 (95% CI: 7169 –
8350). The linear regression revealed that predisposing (region), enabling (health
insurance coverage) and need (charlson comorbidity score) factors were signifi-
cantly associated with prescription drug expenditures. Patients from the Midwest
region had 65% higher prescription expenditure than the west region patients.
Patients with public insurance had 164% higher prescription expenditures than
uninsured patients. One unit increase in charlson comorbidity score was associ-
ated with 28% higher prescription drug expenditure. CONCLUSIONS: The total
prescription drug expenditures accounted for nearly half of total medical expen-
diture in patients with multiple sclerosis. In addition to need factors, the predis-
posing and enabling factors played an important role in influencing prescription
drug expenditures in patients with multiple sclerosis.
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MANAGED CARE AND PHYSICIAN PERCEPTIONS OF NOVEL TREATMENTS IN
MULTIPLE SCLEROSIS
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OBJECTIVES: The objective of this research is to understand emerging value per-
ceptions of novel treatments in Multiple Sclerosis from the perspective of US Man-
aged Care Organization decision makers and prescribing physicians. METHODS:
Explorative primary research interviews (n35) were conducted with a sample of
Managed Care Organization decision makers, practicing neurologists, hospital
pharmacy directors, and specialty pharmacy distribution managers. The sample
was composed of national and regional payers representing various patient popu-
lations with commercial or government-funded coverage. Interviews were con-
ducted from April to June 2011 and consisted of individual one-hour phone inter-
views. Survey questions were focused on identifying payer perceptions of unmet
need in current Multiple Sclerosis (MS) disease management, payer and physician
reactions to the first oral treatment entrant (Gilenya), and projections for changes
in treatment algorithms and benefit design upon availability of additional oral
therapies. Qualitative surveymethods for eliciting stated preferences for formulary
management decisions were used. RESULTS: Payers and physicians described the
unmet need in MS treatment being driven by the absence of optimal disease-
modifying treatments and evidence correlating available treatments to long-term
outcomes. Payers are sensitive to recent price increases in the category and man-
agement practices in MSmay becomemore aggressive in the near-term as compe-
tition for value increases. Payers and physicians anticipate future oral treatments
in development to induce increased in oral drug initiation but do not anticipate
rapid conversion from injectable therapy to oral therapy. CONCLUSIONS: Payers
and prescribers acknowledge oral therapy options for MS as an expansion in treat-
ment options offering more convenient administration. Rising cost of therapy and
evidence of long-term outcome improvement with their utilization remain con-
cerns in supporting the value of these treatments.
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MODELS AND IMPLICATIONS FOR DEVELOPMENT OF REAL-WORLD DATA
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BACKGROUND: US payers often employ a fail-first approach to multiple sclerosis
(MS), imposing multiple steps through therapies as patients relapse, progress and
accumulate disability. However, within the past year, one managed care organiza-
tion has piloted an outcomes-based contract in MS. Tier status and discounts will
be tied to medication adherence, avoidance of relapses and subsequent hospital-
izations. At the same time, the MS therapy pipeline is rapidly evolving, and may
offer opportunities for contracting based on volume, or a portfolio of products for
multiple lines of therapy.OBJECTIVES: To gauge the level of interest among payers
in piloting value-based insurance designs (VBID) for oral and intravenous therapies
in MS. Additionally, to identify characteristics of plans most likely to implement
VBID; and to highlight implications for development of real-world outcomes data
to support innovative contracting. METHODS: Pharmacy and medical directors of
managed care payers will be asked to rate their level of interest in different benefit
designs for oral and intravenous MS therapies. Benefit designs include integrated
medical/pharmacy benefits; open access plans; pathways based on futility rules;
outcomes-based contracting; and risk-sharing tied to avoidance of hospitaliza-
tions. The interview sample will include a mix of plans with different approaches
to use of specialty pharmacy in MS and additional management practices.
RESULTS: Critical success factors for VBID (such as ability to link datasets from
pharmacy and medical claims) will be identified. In addition, specific outcomes
required to design or implement VBID, such as impact of time on ineffective ther-
apy and/ormedication non-adherence, will be prioritized based on payer feedback.
Lastly,metrics for demonstrating return on investment fromVBID inMS, including
PMPM as well as drug budget impact and medical cost offsets, will be elucidated.
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CONCLUSIONS: The design of VBID initiatives in MS can inform outcomes and
contracting strategies for manufacturers of MS therapies.
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OBJECTIVES: To gain insights into technology assessments of Alzheimer’s disease
and to reveal the diverse influences on reimbursement decisions in the intercon-
nected HTA universe. METHODS: Eighty-four reports published by twenty two
Health Technology Assessment (HTA) agencies between 2000 and 2012 were iden-
tified that evaluate treatments for Alzheimer’s disease (fifty eight of them assessed
pharmaceuticals). Data extracted from those reports was supplemented with pub-
lished information from other sources and divided into data categories (agencies,
institutions, assessments, and people). Multiple attributes such as location, affili-
ation, membership, type of technology, decision on technology, degree of influ-
ence, type of influencewere assigned to each category and to connections between
them. The visual analysis software and social networking analysis techniques
were applied to this complex and densely interconnected dataset to observe the
engagement and influence of various actors in reimbursement decisions.
RESULTS: The visual analysis enabled to reveal commonalities and differences of
approaches in evaluating Alzheimer’s treatments between agencies (decisions vs
patient population, decision drivers). It also allowed identifying patterns of collab-
oration on specific assessments where agencies were referring to each other, re-
ferring to the same sources such as Cochrane reviews, European Collaboration
Initiatives (Alzheimer Europe, European Federation of Neurological Societies, Eu-
ropean Medicines Agency Guideline), professional association guidelines (Alzhei-
mer disease association, American College of Physicians). CONCLUSIONS: Alzhei-
mer’s disease HTA pathway is known for the disparities in decisions and
approaches among agencies. Applying social network analysis allowed identifica-
tion of patterns ofmutual influence and indirect collaboration in the bigger context
of these decisions.
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TREATMENT, COMPLIANCE AND RELAPSE SEVERITY: USING COMPARATIVE
EFFECTIVENESS RESEARCH TO GUIDE THE DESIGN OF OUTCOMES BASED
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OBJECTIVES: To assess the utility of comparative effectiveness research in guiding
the development of outcome based contracts.METHODS: The I3 InVision database
was utilized to identify continuously enrolled patients between 18 and 64 years of
age with 2 diagnoses of multiple sclerosis (MS) (ICD-9-CM of 340.xx).Receipt of a
disease modifying therapy (DMT), with first such date was identified as the index
date. Severe relapsewas defined as either 1) a patient hospitalizedwith a diagnosis
of MS in the post-period or a patient receiving a claim of an outpatient visit with
accompanying use of IVmethylprednisolone. Univariate statistics (ANOVAandChi
Square) were used to compare baseline patient characteristics.The probability of
relapse was assessed using logistic controlling for patient characteristics (age, sex,
region of residence, and insurance product), intent-to-treat, disease modifying
therapy, general health (Charlson Index, medical ADL, prior relapse), and medica-
tion possession ratio (MPR). Differences in charges between the three groups were
assessed using a generalized linear model with gamma distribution and log-link.
RESULTS:A total of 2302 continuously enrolled patientsmet study criteria between
the dates of January 1, 2006 through March 31, 2011. Fourteen percent (14.54%; n 
333) and 13.79% of patients experienced a severe relapse requiring hospitalization
and/or outpatient IV Methylprednisolone use, respectively.Univariate statistics re-
vealed differences across groups with individuals with higher pre-period Charlson
Index (p  0.001), higher pre-period Medical ADL limitation proxy (p  0.001) and
higher numbers of pre-period severe relapse (p  0.001). Lower MPR across the
duration of the post period (p  0.001) and patients enrolled in independent or
preferred provider organization (p  0.001) more likely to experience a severe re-
lapse in the post-period. CONCLUSIONS: Comparative Effectiveness Research
(CER) is an important tool that can be beneficial to inform the design and imple-
mentation of outcome based contracting between health plans and pharmaceuti-
cal manufacturers.
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IDENTIFYING A CONDITION WITH NO ICD-9-CM DIAGNOSIS CODE FROM
ADMINISTRATIVE CLAIMS DATA: POST-STROKE PATIENTS WITH
PSEUDOBULBAR AFFECT
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OBJECTIVES: Pseudobulbar affect (PBA) is a neurological condition characterized by
uncontrolled outbursts of laughter or crying. It occurs secondary to brain injury or
neurologic disease. PBA is often confused with other mental health (MH) condi-
tions, and is challenging to identify retrospectively with claims data because an
ICD-9-CM diagnosis code was not designated until late 2011. PBA is often treated
with antidepressants, anticonvulsants, antipsychotics, or anxiolytics. Estimated
prevalence of PBA secondary to stroke is 7% to 50%. Our study objective was to
identify PBA in a population of post-stroke patients. METHODS: Commercial and
Medicare Advantage members with incident stroke from January 1, 2007 to Febru-
ary 28, 2010 were identified with retrospective claims data from a large US health
plan. Patients were continuously enrolled for 12 months pre- and post-stroke.
Those with: stroke care, MH conditions (depression, bipolar, generalized anxiety or
personality disorders), antidepressants, or diagnoses of emotional lability (ICD-9
799.24, 310.8x) pre-stroke were excluded. Post-stroke PBA was identified with:
ICD-9 codes for emotional lability;1 MH-related ambulatory visit; or1 claim for
a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine
reuptake inhibitor (SNRI) plus 1 claim for anticonvulsant, antipsychotic, or anx-
iolytic within 6months post-stroke. Sensitivity of the criteria was tested by requir-
ing more medication claims or adding MH-related hospitalization. RESULTS: The
study population comprised 9408 post-stroke patients. The PBA criteria identified
605 (10.3%) of commercial and 253 (7.1%) ofMedicare Advantage subjects. Less than
1% had diagnoses indicating emotional lability. Stricter medication criteria re-
duced the PBA cohort2 percentage points, indicating most patients hadmultiple
SSRI, SNRI, and other medication fills. MH-related hospitalizations increased the
PBA cohort 1 percentage point. Overall, 8.6-11.1% of commercial and 6.6-7.9% of
Medicare Advantage patients had potential PBA, depending on criteria.
CONCLUSIONS: The criteria identified a stable potential PBA cohort within the
range of estimated PBA prevalence.
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THE EFFECT OF COADMINSTRATION OF NICOTINAMIDE AND CALCIUM-BASED
PHOSPHATE BINDER ON HYPERPHOPHATEMIA IN PATIENTS UNDERGOING
HEMODIALYSIS
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OBJECTIVES:Assessment the safety and the efficacy of nicotinamide as adjunctive
therapy to calcium carbonate (as phosphate binder).METHODS: Study design and
setting: A prospective, interventional, open-labeled, case control randomized trial
was performed at Ain Shams University Specialized Hospital and Al Motamayz
hemodialysis center, Cairo, Egypt, from August 2010 to December 2010.
PATIENTS AND METHODS: Sixty hemodialysis patients with serum phosphorus
level  5.0 mg/dl were classified into two groups; group I (control group) in which
patients received calcium carbonate tablets in dose of 500mg to 1000mg three t.i.d.
And group II (study group) in which patients received calcium carbonate in dose of
500mg to 1000mg t.i.d. and nicotinamide tablets in a dose titrated to 1000mg/day
for 8 weeks. Serum calcium, phosphorus and intact parathyroid hormone were
measured at week 1 and 9 to assess the efficacy of treatment. RESULTS: Fifty-six
patients successfully completed the trail. Serum phosphorus level falls signifi-
cantly from 6.75 to 5.47 mg/dl with group II and not with group I (from 6.46 to 6.53
mg/dl). A concurrent fall in calcium- phosphorus product was seen with nicotin-
amide treatment (from 58.7 to 48.55mg2/dl2), whereas serum calcium, intact para-
thyroid hormone, uric acid, platelet count, total cholesterol, hemoglobin, AST, and
ALT remained stable in both arms. A trend toward increasing HDL and reducing
LDL and triglycerides were reported in nicotinamide group however the overall
changes were statistically non significant. Diarrhea and other gastrointestinal dis-
turbances symptoms were the major adverse effects seen with nicotinamide
treatment. CONCLUSIONS:Nicotinamide in single dose of 1000mg daily can effec-
tively reduce serum phosphorus level when administered with calcium carbonate
(as phosphate binder) with less potential side effects.
PUK2
ODDS OF MISSED HEMODIALYSIS SESSIONS ARE INCREASED DURING HOLIDAY
PERIODS AMONG IN-CENTER HEMODIALYSIS PATIENTS
Crawford SO, Wang X, Oberai PC, Sibbel SP
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OBJECTIVES: Missed dialysis sessions place a significant economic burden on di-
alysis facilities, compromising dialysis delivery and increasing the cost of hemo-
dialysis. Longer interdialytic intervals have been shown to increase morbidity and
mortality and may result in increased time on dialysis. We therefore assessed the
likelihood of missed dialysis sessions during holiday periods, which may prolong
interdialytic intervals. METHODS: We evaluated missed sessions during holiday
and non-holiday periods among 2474 in-center hemodialysis patients from 2006-
2010. We assessed 5 holidays (Memorial day, Independence Day, Labor Day,
Thanksgiving, and Christmas/New Years) and compared the proportion of missed
sessions in the week surrounding the holiday relative to non-holiday periods. A
3-week interval was utilized for Christmas/New Years. Generalized binomial mod-
els were fit over time and adjusted for potential confounders including age, race,
gender, dialysis vintage and vascular access. RESULTS: From 2006-2009, we ob-
served a higher proportion ofmissed sessions over Thanksgiving andChristmas. In
particular, Christmas was associated with a 5.8-fold (0.218 vs. 0.038, p0.0001) and
3.7-fold (0.241 vs. 0.065, p0.0001) higher proportion compared to the non-holiday
periods in 2008 and 2009, respectively. Conversely, the proportion of missed ses-
sions during Memorial Day, Independence Day, and Labor Day did not differ from
non-holidays. Thanksgiving (OR: 1.21, 95% CI 1.10, 1.32) and Christmas (OR: 3.88,
95% CI (3.68, 4.09) were both associatedwith a higher odds ofmissed sessions, even
after adjusting for potential confounders. CONCLUSIONS: The Thanksgiving and
Christmas travel periods were associated with a higher likelihood of missed dial-
ysis sessions. Increased travel away from dialysis facilities, overeating, and higher
fluid intake may all contribute, suggesting a continued need for vigilant patient
communication during holidays to help mitigate the economic and adverse im-
pacts of missed dialysis sessions. Further research should verify the association in
larger samples and assess the economic impact of missed hemodialysis sessions.
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